This is one of the most common questions patients ask before committing to stem cell therapy and it deserves a straight answer rather than a sales pitch. The short version is that some patients see meaningful improvement after a single session, while others benefit from a planned course of treatment. The difference depends on the nature of the condition being treated, how the cells work once administered, and what your physician finds during follow-up.
Here is what actually drives that decision.
How Mesenchymal Stem Cells Work in the Body
Before discussing frequency, it helps to understand what stem cells do once they are administered. UC-MSCs do not simply integrate into damaged tissue and stay there permanently. Their primary mechanism is paracrine signalling — they release growth factors, anti-inflammatory molecules, and extracellular vesicles that instruct surrounding cells to reduce inflammation and begin repair. This signalling activity is powerful, but it is time-limited.
Research into MSC behaviour after infusion shows that the cells themselves are gradually cleared from the body over days to weeks. Their signalling effects can persist beyond their physical presence, but the active phase of therapeutic action is not indefinite. This is a key reason why the question of repeat dosing exists at all: once that signalling window closes, a patient with an ongoing inflammatory condition may see their symptoms begin to creep back.
When One Session May Be Sufficient
For conditions that are relatively contained — early-stage joint damage, acute inflammatory episodes, or situations where the goal is supporting a specific healing process — a single session can produce results that hold over time. If the underlying tissue has enough residual capacity to respond to the signals the cells provide, one round of treatment may be enough to reset the inflammatory environment and allow the body’s own repair processes to take over.
Follow-up assessment is essential here. A patient who responds strongly to an initial session and shows stable improvement at three and six months may not need further treatment at all. The goal is not to maximise sessions — it is to achieve a durable clinical outcome with the minimum intervention necessary.
When Repeated Sessions Make Clinical Sense
Chronic conditions are a different picture. Knee osteoarthritis, neurological conditions, and other degenerative processes are not one-time events — they are continuous biological processes. A single infusion addresses inflammation at a point in time, but it cannot permanently halt a condition driven by long-standing structural damage.
Repeat dosing allows the therapeutic effect to be sustained across a longer window. Research in knee osteoarthritis and spinal cord injury has found that multiple sessions produce more durable improvements than a single dose. That said, timing matters — sessions spaced too closely together, before the previous round of signalling has fully played out, are unlikely to add meaningful benefit. Intervals should be based on clinical response, not a fixed calendar.
What Drives the Decision at EDNA Wellness
At EDNA Wellness, treatment planning is not done from a template. Every case is reviewed individually by our surgeon team, led by Dr. Pongwat Polpong, Chief Physician and neurosurgeon. For some patients, a single session with structured follow-up is the right starting point. For others, two or three sessions over six to twelve months is more likely to produce lasting improvement. Either way, the plan is reviewed at each follow-up based on how the patient is actually responding — and we do not recommend additional sessions unless there is a sound clinical reason to do so.
The Honest Takeaway
There is no universal answer to how many stem cell sessions a person needs. The question is really about matching the treatment approach to the biology of the condition understanding that a chronic, ongoing inflammatory process will likely require a different strategy than an acute one. What matters is that the decision is made on clinical grounds, reviewed at each stage, and adjusted based on real patient response rather than a fixed protocol.
If you are considering stem cell therapy and want to understand what a realistic treatment plan might look like for your specific situation, our team is available to walk you through it.
About EDNA Wellness
EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).
All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.
For more information or to book a consultation:
LINE: @ednawellness
WhatsApp: +66 (0) 64 505 5599
www.ednawellness.com
References
- Abbaspanah B, et al. Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease. PMC. 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11204151/
- Caplan AI, et al. New Paradigms in Cell Therapy: Repeated Dosing, Intravenous Delivery, Immunomodulatory Actions, and New Cell Types. Stem Cells Transl Med. 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6050028/
- Gnecchi M, et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667788/
- Chen X, et al. Effects of microenvironment and biological behavior on the paracrine function of stem cells. Front Endocrinol. 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425798/
- Efimenko A, et al. Paracrine-mediated rejuvenation of aged mesenchymal stem cells is associated with downregulation of the autophagy-lysosomal pathway. NPJ Aging. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9293998/
- Systematic review on single vs. repeated MSC injections for knee osteoarthritis — Stem Cell Research & Therapy, 2025 https://link.springer.com/article/10.1186/s13287-025-04638-2
